查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太地区 AI 辅助医学影像市场
市场调查报告书
商品编码
1796156

亚太地区 AI 辅助医学影像市场

APAC AI-assisted Medical Imaging Market
出版日期: | 出版商: Marketstrat, Inc. | 英文 102 Pages | 订单完成后即时交付

价格

报告元资料

  • 研究方法与品质保证：双重视角（自上而下的漏斗模型 + 自下而上的获取率引擎），记录的品质保证循环（协调、监管差距、证据新鲜度、ASP 健康状况）。
  • 格式 PDF（分析师评论、图表和国家细分）。

目标范围

  • 检查方式（CT、MRI、X 光/DR、超音波、PET/核子医学）；
  • 临床领域（肿瘤科、神经内科/中风、心臟科、呼吸/肺科、MSK/骨科、全科）；
  • 应用（提高诊断准确性和分类、效率和数据处理（工作流程）、早期检测和异常、预后和治疗（准确性）、影像增强和剂量优化、分割和特征提取、跨模态整合）；
  • 收入来源（硬体、软体、服务、云端/按使用付费）；
  • 最终用途（医院、诊断影像中心、诊所、远距放射科、其他）；
  • 人工智慧技术（深度学习、电脑视觉、机器学习、自然语言处理、机器人技术、专家系统）。
  • 预测（2023-2032）：中国、日本、印度、韩国、澳洲及世界其他地区（亚太地区）

内容（仅限亚太地区的框架和工具）

  • GTM 成长与成熟度 - 亚太地区供应商地图、监管速度、汽车製造商 AI 安装率、GTM 准备就绪雷达以及国家/地区层面的格局和时间表（中国、日本、印度、韩国、澳新银行、亚太地区）。

为何撰写本报告？

亚太地区是 AI 影像处理领域成长最快的地区，复合年增长率约为 31%，从 2023 年的 6.1 亿美元增长至 2032 年的 73 亿美元，并将在未来十年内超越欧洲。买家需要针对特定区域的证据、连接阶梯以及针对特定国家的GTM工具，才能从试点走向规模化。这份 "脉搏报告" 以区域为重点，提供了这些内容。

购买指南

  • 影像设备原始设备製造商 (OEM)、PACS/VNA 和云端供应商正在建造亚太地区的捆绑包和投标方案。
  • 纯人工智慧厂商正在针对中国、印度、东协、日本/韩国和纽西兰在地化模组和定价。
  • 供应商网路（医院集团、远端影像中心）计画推出企业级 "AI 商店" 。
  • 投资者和通路伙伴正在仔细审查证据、监管速度和GTM成熟度。

买方利益

  • 1.根据国家/地区和细分市场评估投资机会，并结合与附加率假设相关的可靠数据（CT - 新增单位的 10%，MR - 8%，DR - 6% 基准年）。
  • 2.使用区域框架（GTM 的成长和成熟度、监管状态、GTM 准备）和特定国家/地区的分层格局/时间表，确定优先发展领域。
  • 3.使用监管和采购清单（NMPA、PMDA、MFDS、TGA、HSA、CDSCO）、云端/资料驻留提示和定价原型（许可证 vs. 按使用付费）来实现市场在地化。
  • 4.降低定价和部署风险，结合实际情况提供资料（OEM 与纯厂商的占有率划分、改装占有率、组装率阶梯），并预测未来 12 个月的快速行动。
  • 5. 证据和品质保证 (QA) 准备 - 所有表格和分割都经过记录在案的品质保证 (QA) 循环，我们引用了亚太模型中使用的证据堆迭。

概览与要点

  • 亚太地区成长趋势：6.1 亿美元至 73 亿美元（2023-2032 年），复合年增长率为 31%，到 2032 年，亚太地区在全球市场的占有率将接近 30%。
  • 收入集中度：CT/MR 将维持核心地位，印度/东协的 POCUS 超音波和低频段 DR 将成为最快的单位规模驱动力，PET/核子医学将从肿瘤治疗诊断领域发展壮大。
  • 临床引擎：到 2032 年，肿瘤学、神经病学（中风）和心臟病学将占绝对增长的 75%。
  • 收入结构变化：软体 + 云端/按使用付费将快速扩张（日本/韩国/澳新地区为企业套件，印度/东协地区为按研究付费）。
  • 依从性基线：CT 约为 10% → 随着 OEM 捆绑包的增加而增加，MR 约为 8%，DR 约为 6%。
  • 12 个月预期： 在各市场（NMPA/PMDA/MFDS/TGA/HSA/CDSCO）的顶级模组申请、本地云预验证（数据驻留）、AI 侦察 + 卒中分诊（日本/韩国/澳新）以及 DR 胸腔/超声心动图 AI 按研究（印度/东盟）方面领先。

研究方法与品质保证

此预测将亚太地区自上而下的总数与全球汇总资料以及自下而上的按模式（出货量、安装基数升级、工厂与改装附件、本地 ASP 频段）的附件率流程进行比较。亚太地区模型由监管线（NMPA/PMDA/MFDS/TGA/HAS/CDSCO）、印度 ABDM 数位健康轨道以及同行评审的 RWE 提供支援。四个品质保证循环用于检查国家/模式协调差异（小于 0.5%）、监管计数差异、证据新鲜度以及平均服务提供者 (ASP) 健康状况。

目录

章节1-摘要整理

章节2-调查手法

章节3-亚太地区(亚太地区)市场

  • 规模、发展轨迹与战略重要性
  • 需求推动因素与不利因素
  • 竞争与合作格局
  • 策略集群与市场进入细微差别
  • 策略建议
  • 法规/政策（新功能或说明）
  • 亚太地区 AI 成像市场（按国家/地区划分）
  • Markintel GTM 成长与成熟度矩阵 -亚太地区
  • 併购观察名单 - 亚太地区
  • 监管速度 - 亚太地区
  • 汽车厂商 AI 采用率 - 亚太地区
  • GTM 概览 - 亚太地区
  • 亚太地区快速策略提示

章节4-中国市场

  • 中国 - 市场概览与策略摘要 (2023-2032)
  • 策略要点
  • 中国市场预测 (2023-2032)
  • Markintel 成长成熟度矩阵 - 中国医学影像 AI
  • Markintel 生态系协作矩阵 - 中国
  • Markintel 解采用率与成长矩阵 - 中国
  • GTM 概览 - 中国

章节5-日本市场

  • 市场概览与策略摘要：日本
  • 战略展望
  • 行动要点
  • 日本市场预测 (2023-2032)
  • Markintel 解采用率与成长矩阵 - 日本
  • Markintel 生态系协作矩阵 - 日本
  • 市场进入 (GTM) 策略 - 日本

章节6-印度市场

  • 市场概览与分析
  • 市场机制
  • 阻碍因素图
  • 竞争温度
  • 可操作机会 (2024-2026)
  • 未来建议（依参与者类型）
  • 定义成功
  • 印度市场预测 (2023-2032)
  • Markintel 解采用率与成长矩阵 - 印度
  • Markintel 生态系协作矩阵 - 印度
  • 竞争格局 -印度
  • GTM 概览 - 印度

章节7-韩国市场

  • 市场总结与概况：韩国
  • 韩国市场预测 (2023-2032)
  • GTM 概览 - 韩国

章节8-澳洲市场

  • 市场概览与分析
  • 市场结构与成长动力
  • 细分市场热点（定性分析）
  • 竞争格局
  • 策略影响与 GTM 优先事项
  • 行动导向建议（未来 12 个月）
  • 澳洲市场预测 (2023-2032)
  • GTM 概览 - 澳大利亚

第9章 -其他的亚太地区市场

  • 市场概览与分析
  • 亚太其他地区市场预测 (2023-2032)
  • GTM 概览 - 亚太其他地区
Product Code: MINTP-M01122

Report Metadata

  • Methodology & QA: Dual lens (top down funnel + bottom up attach rate engine) with a documented QA loop (reconciliation, regulatory diffs, evidence freshness, ASP sanity).
  • Format: PDF (analyst narrative, charts, country breakouts).

Scope

  • Modalities (CT, MRI, X ray/DR, Ultrasound, PET/Nuclear);
  • Clinical areas (Oncology, Neurology/Stroke, Cardiology, Respiratory/Lung, MSK/Ortho, General);
  • Applications (Improved Diagnostic Accuracy & Classification, Efficiency & Data Handling (Workflow), Early Detection & Abnormality, Prognosis & Treatment (Precision), Image Enhancement & Dose Optimization, Segmentation & Feature Extraction, Integration Across Modalities);
  • Revenue streams (Hardware, Software, Service, Cloud/Pay per Use);
  • End use (Hospitals, Imaging Centers, Clinics, Teleradiology, Other);
  • AI Technology (Deep Learning, Computer Vision, Machine Learning, NLP, Robotics, Expert Systems).
  • Forecasts (2023-2032): China, Japan, India, South Korea, Australia, Rest of Asia-Pacific (ROAPAC)

What's inside (APAC only frameworks & tools)

  • GTM Growth & Maturity - APAC vendor map; Regulatory Velocity; OEM AI Attach Rate; GTM Readiness Radar; Country tiered landscapes & timelines (China, Japan, India, South Korea, ANZ, ROAPAC).

Why This Report

APAC is the fastest growing region in AI imaging, moving from ~US$0.61B (2023) to ~US$7.3B (2032) -about 31% CAGR-and overtakes Europe before decade end. Buyers need region specific evidence, attach rate ladders, and country GTM tools to move from pilots to scale; this Pulse report delivers exactly that, in one region focused volume.

Who Should Buy

  • Imaging OEMs, PACS/VNA and cloud vendors building APAC bundles and tenders
  • AI pure plays localizing modules and pricing for China, India, ASEAN, Japan/Korea, and ANZ
  • Provider networks (hospital groups, teleradiology hubs) planning enterprise "AI store" rollouts
  • Investors and channel partners vetting evidence, regulatory velocity and GTM maturity

Buyer Benefits

  • 1. Size the opportunity by country and segment with defendable numbers tied to attach rate assumptions (CT ~10% of new units; MR ~8%; DR ~6% base year).
  • 2. Prioritize where to play using regional frameworks (GTM Growth & Maturity, Regulatory Velocity, GTM Readiness) and country tiered landscapes/timelines.
  • 3. Localize go to market with regulatory and procurement checklists (NMPA, PMDA, MFDS, TGA, HSA, CDSCO), cloud/data residency cues, and pricing archetypes (license vs. pay per use).
  • 4. De risk pricing & deployment with Numbers in Context (OEM vs. pure play split, retrofit share, attach rate ladder) and Pulse Quick Actions for the next 12 months.
  • 5. Evidence & QA ready-every table and split passes a documented QA loop and cites the evidence stack used in the APAC model.

Snapshots & Takeaways

  • APAC growth arc: ~US$0.61B -> ~US$7.3B (2023-2032), ~31% CAGR; APAC's share of the global market nears 30% by 2032.
  • Where revenue concentrates: CT/MR remain the core; fastest unit scale comes from POCUS ultrasound and low bandwidth DR in India/ASEAN; PET/Nuclear grows off oncology theranostics.
  • Clinical engines: Oncology, Neurology (stroke), and Cardiology together deliver ~75% of absolute growth to 2032.
  • Shift in revenue mix: Hardware share declines as fleets modernize; Software + Cloud/Pay per Use expand fastest (enterprise suites in JP/KR/ANZ; pay per study in India/ASEAN).
  • Attach rate baseline: CT ~10% -> rising with OEM bundles; MR ~8%; DR ~6%; retrofit dominates incremental dollars as the installed base upgrades.
  • What to act on in 12 months: File top modules per market (NMPA/PMDA/MFDS/TGA/HSA/CDSCO), pre validate on local clouds (data residency), lead with AI recon + stroke triage (JP/KR/ANZ) and DR chest/echo AI pay per study (India/ASEAN).

Methodology & QA

Forecasts reconcile top down APAC totals to the global rollup and bottom up attach rate flows by modality (shipments, installed base upgrades, factory vs. retrofit attach, and local ASP bands). The APAC model is anchored by regulatory lines NMPA / PMDA / MFDS / TGA / HAS / CDSCO), ABDM digital health rails for India, and peer reviewed RWE. A four point QA loop checks reconciliation variance (Less than or equal to 0.5%), regulatory count deltas, evidence freshness, and ASP sanity for each country/modality.

TABLE OF CONTENTS

SECTION 1 - EXECUTIVE SUMMARY

  • The 25-second Read
  • Size & Pace (Who Contributes What by 2032)
  • Where Growth Concentrates
  • Country/Cluster Snapshots
  • APAC Watchlist (What to Act on in the Next 12 months)
  • Pulse Quick Actions (12 Months)

SECTION 2 - RESEARCH METHODOLOGY

  • Objective
  • Dual-lens Architecture
  • APAC-specific Evidence & Inputs
  • Model Calibration Choices (APAC)
  • Limitations & Mitigations (APAC)
  • Quality Assurance Loop

SECTION 3 - ASIA-PACIFIC (APAC) MARKET

  • Size, Trajectory & Strategic Importance
  • Demand Drivers & Headwinds
  • Competitive & Partnership Landscape
  • Strategic Clustering & Go-to-Market Nuances
  • Strategic Recommendations
  • Regulatory / Policy (What's New or Clarified)
  • AI Imaging Market by Country - APAC
  • Markintel GTM Growth and Maturity Matrix - APAC
    • Competitive Data Set - APAC
    • Numbers-in-Context - APAC
    • Strategic Takeaways - APAC
    • Growth & Maturity Highlights - APAC
  • M&A Watchlist - APAC
  • Regulatory Velocity - APAC
  • OEM AI Attach Rate - APAC
    • Attach-Rate Trends - APAC
    • Factory vs Retrofit Attach
  • GTM at-a-Glance - APAC
    • GTM Readiness Radar - APAC
    • Tiered Customer Landscape - APAC
    • GTM Timeline - APAC
    • Adjacency Opportunity Matrix - APAC
    • Country-Cluster Framework - APAC
    • White Space Partner Framework - APAC
    • Regulatory Funding Heatmap - APAC
    • Channel x Pricing Matrix - APAC
  • Fast Strategic Cues - APAC

SECTION 4 - CHINESE MARKET

  • China - Market Overview & Strategic Summary (2023-2032)
    • Urban-Rural Duality Matters
  • Strategic Takeaways
  • Chinese Market Forecasts (2023-2032)
    • Chinese Market by Clinical Area (2023-2032)
    • Chinese Market by Modality (2023-2032)
    • Chinese Market by Revenue Stream (2023-2032)
    • Chinese Market by Clinical Application (2023-2032)
    • Chinese Market by End-Use Organization (2023-2032)
    • Chinese Market by AI Technology (2023-2032)
  • Markintel Growth Maturity Matrix - China AI in Medical Imaging
    • Executive Commentary
    • Cross-Quadrant Insights & Tactical Guidance
    • Priority Recommendations (next 18 months)
    • Competitive Dataset - China
  • Markintel Ecosystem Collaboration Matrix - China
    • Decoding the 2 x 2 and Turning it into Action
    • Three Rules for Winning the Collaboration Game
    • Quick hit Actions for BD teams (Next Two Quarters)
  • Markintel Solution Adoption and Growth Matrix - China
    • Translating the Matrix into Action
    • Execution Priorities by Function
    • "First 100-Days" Checklist
    • Metrics that Matter
    • Operating Roadmap Takeaway
  • GTM at a Glance - China
    • GTM Readiness Radar - China
    • Tiered Customer Landscape - China
    • GTM Timeline - China
    • Adjacency-Opportunity Radar - China
    • Regulatory Funding Heatmap - China
    • Channel x Pricing Matrix - China
    • White Space Partnership Matrix - China

SECTION 5 - JAPANESE MARKET

  • Market Overview & Strategic Summary: Japan
  • Strategic Outlook
  • Action Points
  • Japanese Market Forecasts (2023-2032)
    • Japanese Market by Clinical Area (2023-2032)
    • Japanese Market by Modality (2023-2032)
    • Japanese Market by Clinical Application (2023-2032)
    • Japanese Market by End-Use Organization (2023-2032)
    • Japanese Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - Japan
    • Turning the Matrix into an Operating Road Map for Japan (2024 28)
  • Markintel Ecosystem Collaboration Matrix - Japan
    • Turning the Matrix into an Operating Roadmap
    • Playbook Highlights by Quadrant
    • Risk Checkpoints & Mitigations
  • Go-to-Market (GTM) Playbook - Japan
    • GTM Readiness Radar - Japan
    • Tiered Customer Landscape - Japan
    • GTM Timeline - Japan
    • Adjacency Opportunity Radar - Japan
    • Regulatory Funding Heatmap - Japan
    • Channel x Pricing Matrix - Japan
    • White Space Partnership Matrix - Japan
    • Fast Strategic Cues

SECTION 6 - INDIAN MARKET

  • Market Overview & Analysis
  • Market Mechanics
  • Constraint Map
  • Competitive Temperature
  • Actionable Opportunities (2024-26 Window)
  • Go Forward Recommendations (by player type)
  • What Success Looks Like
  • Indian Market Forecasts (2023-2032)
    • Indian Market by Clinical Area (2023-2032)
    • Indian Market by Modality (2023-2032)
    • Indian Market by Revenue Stream (2023-2032)
    • Indian Market by Clinical Application (2023-2032)
    • Indian Market by End-Use Organization (2023-2032)
    • Indian Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - India
    • Solution Classes and Action Cues
    • Strategic Interpretation & Operating Roadmap
    • One-Page Operating Checklist
  • Markintel Ecosystem Collaboration Matrix - India
    • Operating Roadmap: Leveraging India's Collaboration Matrix
    • Strategic Sequencing (2024 27)
    • Execution Tips
    • Key Metrics to Track
  • Competitive Landscape - India
    • Operating Roadmap
  • GTM at a Glance - India
    • GTM Readiness Radar - India
    • Tiered Customer Landscape - India
    • GTM Timeline - India
    • Adjacency-Opportunity Radar - India
    • Regulatory x Funding Heatmap - India
    • White-Space Partnership Matrix
    • Channel x Pricing Matrix
    • Fast Strategic Cues (Do This First)

SECTION 7 - SOUTH KOREAN MARKET

  • Market Summary & Overview: South Korea
    • Key Market Dynamics
    • Strategic Takeaways
    • Top 3 Recommendations
    • South Korea Market Context
  • South Korean Market Forecasts (2023-2032)
    • South Korean Market by Clinical Area (2023-2032)
    • South Korean Market by Modality (2023-2032)
    • South Korean Market by Revenue Stream (2023-2032)
    • South Korean Market by Clinical Application (2023-2032)
    • South Korean Market by End-Use Organization Type (2023-2032)
    • South Korean Market by AI Technology (2023-2032)
  • GTM at a Glance - South Korea
    • Six-Pillar GTM Readiness Radar - South Korea
    • Tiered Customer Landscape - South Korea
    • Five-Step GTM Timeline - South Korea
    • Adjacency-Opportunity Radar - South Korea
    • Regulatory x Funding Heatmap - South Korea
    • Whitespace Partnership Matrix - South Korea
    • Channel x Pricing Matrix - Typical 2025 Deals
    • Fast Strategic Cues

SECTION 8 - AUSTRALIAN MARKET

  • Market Overview & Analysis
  • Market Structure & Growth Drivers
  • Segment Hotspots (Qualitative Sizing)
  • Competitive Landscape
  • Strategic Implications & GTM Priorities
  • Action-Oriented Recommendations (Next 12 Months)
  • Australian Market Forecasts (2023-2032)
    • Australian Market by Clinical Area (2023-2032)
    • Australian Market by Modality (2023-2032)
    • Australian Market by Revenue Stream (2023-2032)
    • Australian Market by Clinical Application (2023-2032)
    • Australian Market by End-Use Organization (2023-2032)
    • Australian Market by AI Technology (2023-2032)
  • GTM at a Glance - Australia
    • GTM Readiness Radar - Australia
    • GTM Timeline - Australia
    • Adjacency-Opportunity Radar - Australia
    • Regulatory x Funding Heatmap

SECTION 9 - REST OF ASIA-PACIFIC (ROAPAC) MARKET

  • Market Overview & Analysis
    • Regional Clusters
    • Market Dynamics - What's Shaping Buying Decisions
    • Actionable Recommendations
    • Quick-Hit Opportunities by Cluster
    • What Success Looks Like
  • Rest of Asia-Pacific Market Forecasts (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032)
    • Strategic Insights
    • Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032)
  • GTM at a Glance - ROAPAC
    • GTM Readiness Heatmap - ROAPAC Clusters
    • Five-Step GTM Roll Out Timeline (2024 2029) - Keyed to Clusters

List of Tables

  • Table 1: AI Imaging Market by Country - APAC (2023-2032, USD Mill)
  • Table 2: Chinese Market by Clinical Area (2023-2032, USD Million)
  • Table 3: Chinese Market by Modality (2023-2032, USD Million)
  • Table 4: Chinese Market by Revenue Stream (2023-2032, USD Million)
  • Table 5: Chinese Market by Clinical Application (2023-2032, USD Million)
  • Table 6: Chinese Market by End-Use Organization (2023-2032, USD Million)
  • Table 7: Chinese Market by AI Technology (2023-2032, USD Million)
  • Table 8: Japanese Market by Clinical Area (2023-2032, USD Million)
  • Table 9: Japanese Market by Modality (2023-2032, USD Million)
  • Table 10: Japanese Market by Revenue Stream (2023-2032, USD Million)
  • Table 11: Japanese Market by Clinical Application (2023-2032, USD Million)
  • Table 12: Japanese Market by End-Use Organization (2023-2032, USD Million)
  • Table 13: Japanese Market by AI Technology (2023-2032, USD Million)
  • Table 14: Indian Market by Clinical Area (2023-2032, USD Million)
  • Table 15: Indian Market by Modality (2023-2032, USD Million)
  • Table 16: Indian Market by Revenue Stream (2023-2032, USD Million)
  • Table 17: Indian Market by Clinical Application (2023-2032, USD Million)
  • Table 18: Indian Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
  • Table 19: Indian Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
  • Table 20: South Korean Market by Clinical Area (2023-2032, USD Million)
  • Table 21: South Korean Market by Modality (2023-2032, USD Million)
  • Table 22: South Korean Market by Revenue Stream (2023-2032, USD Million)
  • Table 23: South Korean Market by Clinical Application (2023-2032, USD Million)
  • Table 24: South Korean Market End-Use Organization Type (2023-2032, USD Million)
  • Table 25: South Korean Market by AI Technology (2023-2032, USD Million)
  • Table 26: Australian Market by Clinical Area (2023-2032, USD Million)
  • Table 27: Australian Market by Modality (2023-2032, USD Million)
  • Table 28: Australian Market by Revenue Stream (2023-2032, USD Million)
  • Table 29:Australian Market by Clinical Application (2023-2032, USD Million)
  • Table 30: Australian Market by End-Use Organization (2023-2032, USD Million)
  • Table 31: Australian Market by AI Technology (2023-2032, USD Million)
  • Table 32: Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032, USD Million)
  • Table 33: Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032, USD Million)
  • Table 34: Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032, USD Million)
  • Table 35: Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032, USD Million)
  • Table 36: Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032, USD Million)
  • Table 37: Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032, USD Million)

List of Figures

  • Figure 1: APAC Top-Down Funnel - Country Group Mix (2023 vs 2032)
  • Figure 2: Bottom-up Attach Rate Flow APAC (Illustrative)
  • Figure 3: APAC Evidence -- Markintel Regional Model
  • Figure 4: Markintel GTM Growth and Maturity Matrix - APAC
  • Figure 5: Regulatory Velocity - APAC
  • Figure 6: OEM AI Attach Rate - APAC
  • Figure 7: AI Revenue Split - Factory vs Retrofi t - APAC
  • Figure 8: GTM Readiness Radar - APAC
  • Figure 9: Tiered Customer Landscape - APAC (2032)
  • Figure 10: GTM Timeline - APAC (2024-29)
  • Figure 11: Regulatory Funding Heatmap - APAC
  • Figure 12: Markintel Growth Maturity Matrix - China AI in Medical Imaging
  • Figure 13: Markintel Ecosystem Collaboration Matrix - China
  • Figure 14: Markintel Solution Adoption and Growth Matrix - China
  • Figure 15: GTM Readiness Radar - China
  • Figure 16: Tiered Customer Landscape - China (2032)
  • Figure 17: GTM Timeline - China (2024-29)
  • Figure 18: Adjacency-Opportunity Radar - China
  • Figure 19: Regulatory Funding Heatmap - China
  • Figure 20: Markintel Solution Adoption & Growth Matrix - Japan
  • Figure 21: Markintel Ecosystem Collaboration Matrix - Japan
  • Figure 22: GTM Readiness Radar - Japan
  • Figure 23: GTM Timeline - Japan
  • Figure 24: Adjacency Opportunity Radar - Japan
  • Figure 25: Regulatory Funding Heatmap - Japan
  • Figure 26: White Space Partnership Matrix - Japan
  • Figure 27: Markintel Solution Adoption & Growth Matrix - India
  • Figure 28: Markintel Ecosystem Collaboration Matrix - India
  • Figure 29: GTM Readiness Radar - India
  • Figure 30: Tiered Customer Landscape - India
  • Figure 31: GTM Timeline - India
  • Figure 32: Adjacency-Opportunity Radar - India
  • Figure 33: Regulatory x Funding Heatmap - India
  • Figure 34: Six-Pillar GTM Readiness Radar - South Korea
  • Figure 35: Tiered Customer Landscape - South Korea
  • Figure 36: Five-Step GTM Timeline - South Korea
  • Figure 37: Adjacency-Opportunity Radar - South Korea
  • Figure 38: Regulatory x Funding Heatmap - South Korea
  • Figure 39: GTM Readiness Radar - Australia
  • Figure 40: GTM Timeline - Australia
  • Figure 41: Adjacency-Opportunity Radar - Australia
  • Figure 42: Regulatory x Funding Heatmap
  • Figure 43: GTM Readiness Heatmap - ROAPAC Clusters
  • Figure 44: Five-Step GTM Roll Out Timeline (2024 2029) - ROAPAC